Vermillion & White Wealth Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vermillion & White Wealth Management Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-936	Closed	-$55.6K	–	122
2025 Q4	$55.6K	Hold	936	–	–	0.03%	143
2025 Q3	$50.7K	Hold	936	–	–	0.03%	149
2025 Q2	$51.5K	Hold	936	–	–	0.03%	137
2025 Q1	$66.2K	Hold	936	–	–	0.05%	104
2024 Q4	$61.5K	Buy	+936	New	+$62.7K	0.05%	121

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vermillion & White Wealth Management Group's BMRN Position: Q1 2026 in Review

Vermillion & White Wealth Management Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 936 shares — an estimated $55.6K sold.

Vermillion & White Wealth Management Group first reported a position in BMRN in Q4 2024 and held it in 5 quarters. The position peaked at $66.2K in Q1 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Vermillion & White Wealth Management Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Vermillion & White Wealth Management Group sold 936 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $55.6K.
Vermillion & White Wealth Management Group first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 5 quarters.
Vermillion & White Wealth Management Group's BioMarin Pharmaceuticals position peaked at $66.2K in Q1 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Vermillion & White Wealth Management Group's 13F filing for Q1 2026, filed 14 May 2026.